Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FAK and Pyk2: Paralogous Kinases with Opposing Roles in Vasculogenic Mimicry in Triple-Negative Breast Cancer.

International journal of molecular sciences·2026

Same author

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

British journal of haematology·2026

Same author

A ray of hope for early-stage T-cell lymphoma.

Haematologica·2026

Same author

Vitamin D Supplementation and Treatment-Free Survival in Early-Stage CLL: A Real-World Validation Study.

EJHaem·2026

Same author

Psychological distress in patients with hematological malignancies during the 2023-2025 war in Israel: a national survey and comparison with the COVID-19 pandemic.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Same author

Shared decision-making, treatment priorities and communication gaps in chronic lymphocytic leukemia: an Israeli national survey.

Leukemia & lymphoma·2026

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

CD30: an important new target in hematologic malignancies.

Yehuda E Deutsch¹, Tamar Tadmor, Eckhard R Podack

¹Department of Medicine, Division of Hematology-Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.

Leukemia & Lymphoma

|May 31, 2011

Summary

Targeting CD30, a protein found on certain cancer cells like Hodgkin lymphoma and ALCL, shows promise. Antibody-drug conjugates targeting CD30, such as brentuximab vedotin, demonstrate significant efficacy with manageable toxicity in clinical trials.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Pan-myeloid Differentiation of Human Cord Blood Derived CD34⁺ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

Related Experiment Videos

Last Updated: Jun 1, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Pan-myeloid Differentiation of Human Cord Blood Derived CD34⁺ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

CD30 is selectively expressed on various lymphoid and non-lymphoid malignancies, including Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL).
Restricted expression of CD30 on normal cells enables targeted therapy against malignant cells.
CD30, a member of the tumor necrosis factor (TNF)-receptor superfamily, possesses diverse biological functions.

Purpose of the Study:

To review the role of CD30 as a therapeutic target in CD30-expressing malignancies.
To highlight the potential of novel therapeutic strategies, particularly antibody-drug conjugates, for targeting CD30.

Main Methods:

Review of preclinical and clinical data on CD30-targeted therapies.
Analysis of the efficacy and safety profiles of antibody-drug conjugates, such as brentuximab vedotin.
Examination of the biological functions and signaling pathways associated with CD30.

Main Results:

Antibody-drug conjugates targeting CD30 have demonstrated significant clinical activity in early-phase trials.
Brentuximab vedotin has shown striking efficacy in patients with Hodgkin lymphoma and ALCL.
Therapies targeting CD30 exhibit manageable toxicity profiles.

Conclusions:

Targeting CD30 represents a promising therapeutic strategy for CD30-positive hematological and other malignancies.
Antibody-drug conjugates targeting CD30 offer a novel and effective treatment option.
Further investigation into CD30-targeted therapies is warranted for various CD30+ cancers.